Literature DB >> 10951490

Analysis of type T1 and T2 cytokines in patients with prostate cancer.

X Filella1, J Alcover, M A Zarco, P Beardo, R Molina, A M Ballesta.   

Abstract

BACKGROUND: It has been proposed that a dysregulation in the balance between type T1 (IL-2, IFN-gamma) and type T2 (IL-4, IL-10) cytokines may be implicated in the development of cancer.
METHODS: We determined the expression of IL-2, IL-4, IL-10, and IFN-gamma in CD4 and CD8 lymphocytes by flow cytometry in 12 patients with prostate cancer and in 7 healthy subjects. In addition to the basal expression of these cytokines, their expression was also determined, following stimulation of lymphocytes with PMA (phorbol 12-mystirate 13 acetate) and ionomycin.
RESULTS: The basal expression of cytokines was scarce, while following stimulation this increased markedly. On the other hand, there was a dysregulation in the balance between T1 and T2 lymphocytes in patients with prostate cancer. To this effect, in relation to healthy subjects, we observed an increase in IL-10 expression and a decrease in IL-2 expression.
CONCLUSIONS: The disequilibrium observed in the balance between type T1 and type T2 cytokines may be implicated in the evolution of neoplastic disease. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10951490     DOI: 10.1002/1097-0045(20000901)44:4<271::aid-pros2>3.0.co;2-g

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  11 in total

1.  Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation.

Authors:  John R McWhirter; Anke Kretz-Rommel; Alan Saven; Toshiaki Maruyama; Kathleen N Potter; C Ian Mockridge; E Prenn Ravey; Fenghua Qin; Katherine S Bowdish
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-17       Impact factor: 11.205

2.  Serum cytokine profiles in patients with prostate carcinoma.

Authors:  Eri Tazaki; Nobuaki Shimizu; Ryota Tanaka; Masakazu Yoshizumi; Hiroshi Kamma; Shigeru Imoto; Tomoyuki Goya; Kunihisa Kozawa; Atsuyoshi Nishina; Hirokazu Kimura
Journal:  Exp Ther Med       Date:  2011-06-16       Impact factor: 2.447

3.  Administration of a vaccine composed of dendritic cells pulsed with premalignant oral lesion lysate to mice bearing carcinogen-induced premalignant oral lesions stimulates a protective immune response.

Authors:  Anna-Maria A De Costa; Danielle N Justis; Corinne A Schuyler; M Rita I Young
Journal:  Int Immunopharmacol       Date:  2012-05-16       Impact factor: 4.932

4.  Comparative study of frequency of different lymphocytes subpopulation in peripheral blood of patients with prostate cancer and benign prostatic hyperplasia.

Authors:  Stanislav Sotosek; Vlatka Sotosek Tokmadzic; Ines Mrakovcic-Sutic; Maja Ilic Tomas; Marin Dominovic; Vera Tulic; Ivana Sutic; Antun Maricic; Jadranko Sokolic; Alan Sustic
Journal:  Wien Klin Wochenschr       Date:  2011-11-23       Impact factor: 1.704

5.  Tumor-released survivin induces a type-2 t cell response and decreases cytotoxic T cell function, in vitro.

Authors:  Jessica M S Jutzy; Salma Khan; Malyn May Asuncion-Valenzuela; Terry-Ann M Milford; Kimberly J Payne; Nathan R Wall
Journal:  Cancer Microenviron       Date:  2012-02-10

6.  IL-10 -1082 G>A: a risk for prostate cancer but may be protective against progression of prostate cancer in North Indian cohort.

Authors:  Pravin Kesarwani; Dinesh Kumar Ahirwar; Anil Mandhani; Anand Narayan Singh; Divakar Dalela; Anand Narain Srivastava; Rama D Mittal
Journal:  World J Urol       Date:  2009-01-15       Impact factor: 4.226

7.  Plasma concentration of Propionibacterium acnes antibodies and prostate cancer risk: results from an Australian population-based case-control study.

Authors:  G Severi; B A Shannon; H N Hoang; L Baglietto; D R English; J L Hopper; J Pedersen; M C Southey; R Sinclair; R J Cohen; G G Giles
Journal:  Br J Cancer       Date:  2010-07-06       Impact factor: 7.640

8.  Treatment combining RU486 and Ad5IL-12 vector attenuates the growth of experimentally formed prostate tumors and induces changes in the sentinel lymph nodes of mice.

Authors:  Claudia Raja Gabaglia; Alexandra DeLaney; Jennifer Gee; Ramesh Halder; Frank L Graham; Jack Gauldie; Eli E Sercarz; Todd A Braciak
Journal:  J Transl Med       Date:  2010-10-14       Impact factor: 5.531

9.  Interleukin 10 gene rs1800896 polymorphism is associated with the risk of prostate cancer.

Authors:  Hao Chen; Jilei Tang; Nan Shen; Kewei Ren
Journal:  Oncotarget       Date:  2017-08-03

10.  Clinical investigation of the role of interleukin-4 and interleukin-13 in the evolution of prostate cancer.

Authors:  Robert Goldstein; Charles Hanley; Jonathan Morris; Declan Cahill; Ashish Chandra; Peter Harper; Simon Chowdhury; John Maher; Sophie Burbridge
Journal:  Cancers (Basel)       Date:  2011-12-16       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.